Drug profile · INN
sotatercept-csrk
WINREVAIR
sotatercept-csrk (WINREVAIR) is a inhibin beta a chain inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — sotatercept-csrk
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
sotatercept-csrk (WINREVAIR) is a inhibin beta a chain inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Inhibin beta A chain inhibitor
Primary target: Inhibin beta A chain
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Related & competitor drugs
Frequently asked questions
What is sotatercept-csrk?
sotatercept-csrk (WINREVAIR) is a inhibin beta a chain inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for sotatercept-csrk?
WINREVAIR is a marketed brand name for sotatercept-csrk. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sotatercept-csrk?
sotatercept-csrk has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.